Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...

The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...

Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

Ro announced earlier that it is working with Eli Lilly (LLY) and Company to streamline access to Zepbound single-dose vials for Ro patients ...

Global Alzheimer's Platform Foundation (GAP) has partnered with Eli Lilly and Company (NYSE: LLY) for a study comparing blood ...

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the branded drugs, Lilly on Wednesday said it would sell a version of Zepbound ...

Eli Lilly announces $15 billion share buyback plan and 15% dividend boost amidst mixed technical signals. Investors are ...

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...

According to the announcement, the share repurchase program allows for flexibility in purchasing methods, including open ...